Limits...
Polyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.

Li T, Shen X, Chen Y, Zhang C, Yan J, Yang H, Wu C, Zeng H, Liu Y - Int J Nanomedicine (2015)

Bottom Line: Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed.The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification.Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT
Engineering a safe and high-efficiency delivery system for efficient RNA interference is critical for successful gene therapy. In this study, we designed a novel nanocarrier system of polyethyleneimine (PEI)-modified Fe3O4@SiO2, which allows high efficient loading of VEGF small hairpin (sh)RNA to form Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites for VEGF gene silencing as well as magnetic resonance (MR) imaging. The size, morphology, particle stability, magnetic properties, and gene-binding capacity and protection were determined. Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed. The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification. The qualitative and quantitative analysis of cellular internalization into MCF-7 human breast cancer cells by Prussian blue staining and inductively coupled plasma atomic emission spectroscopy analysis, respectively, demonstrated that the Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could be easily internalized by MCF-7 cells, and they exhibited significant inhibition of VEGF gene expression. Furthermore, the MR cellular images showed that the superparamagnetic iron oxide core of our Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could also act as a T2-weighted contrast agent for cancer MR imaging. Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

No MeSH data available.


Related in: MedlinePlus

Hemolysis assay for the Fe3O4@SiO2/PEI nanoparticles. (A) Hemolysis detection by UV-vis spectrophotometer; (B) Mignifation of the circle indicated; (C) Photo of hemolysis at various concentrations of nanoparticles.Notes: The bottom-right inset is the photo of the direct observation of hemolysis by Fe3O4@SiO2/PEI at different concentrations; 0.9% NaCl is the negative control and H2O is the positive control.Abbreviation: PEI, polyethylenimine.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4495783&req=5

f6-ijn-10-4279: Hemolysis assay for the Fe3O4@SiO2/PEI nanoparticles. (A) Hemolysis detection by UV-vis spectrophotometer; (B) Mignifation of the circle indicated; (C) Photo of hemolysis at various concentrations of nanoparticles.Notes: The bottom-right inset is the photo of the direct observation of hemolysis by Fe3O4@SiO2/PEI at different concentrations; 0.9% NaCl is the negative control and H2O is the positive control.Abbreviation: PEI, polyethylenimine.

Mentions: It is essential to investigate the hemocompatibility of nanocarriers for their successful systemic administration.33,34 Therefore, the hemolysis experiment for Fe3O4@SiO2/PEI was carried out to evaluate the impacts of the nanocarriers on RBCs. As show in Figure 6, almost no hemolysis of the RBCs could be detected at the Fe3O4@SiO2/PEI concentrations from 5–80 μg/mL, and only ~2.96% of hemolysis activity was detected at the high concentration of 80 μg/mL. These results indicated that Fe3O4@SiO2/PEI nanocarriers have negligible hemolysis activity and could further be injected intravenously.


Polyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.

Li T, Shen X, Chen Y, Zhang C, Yan J, Yang H, Wu C, Zeng H, Liu Y - Int J Nanomedicine (2015)

Hemolysis assay for the Fe3O4@SiO2/PEI nanoparticles. (A) Hemolysis detection by UV-vis spectrophotometer; (B) Mignifation of the circle indicated; (C) Photo of hemolysis at various concentrations of nanoparticles.Notes: The bottom-right inset is the photo of the direct observation of hemolysis by Fe3O4@SiO2/PEI at different concentrations; 0.9% NaCl is the negative control and H2O is the positive control.Abbreviation: PEI, polyethylenimine.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4495783&req=5

f6-ijn-10-4279: Hemolysis assay for the Fe3O4@SiO2/PEI nanoparticles. (A) Hemolysis detection by UV-vis spectrophotometer; (B) Mignifation of the circle indicated; (C) Photo of hemolysis at various concentrations of nanoparticles.Notes: The bottom-right inset is the photo of the direct observation of hemolysis by Fe3O4@SiO2/PEI at different concentrations; 0.9% NaCl is the negative control and H2O is the positive control.Abbreviation: PEI, polyethylenimine.
Mentions: It is essential to investigate the hemocompatibility of nanocarriers for their successful systemic administration.33,34 Therefore, the hemolysis experiment for Fe3O4@SiO2/PEI was carried out to evaluate the impacts of the nanocarriers on RBCs. As show in Figure 6, almost no hemolysis of the RBCs could be detected at the Fe3O4@SiO2/PEI concentrations from 5–80 μg/mL, and only ~2.96% of hemolysis activity was detected at the high concentration of 80 μg/mL. These results indicated that Fe3O4@SiO2/PEI nanocarriers have negligible hemolysis activity and could further be injected intravenously.

Bottom Line: Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed.The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification.Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT
Engineering a safe and high-efficiency delivery system for efficient RNA interference is critical for successful gene therapy. In this study, we designed a novel nanocarrier system of polyethyleneimine (PEI)-modified Fe3O4@SiO2, which allows high efficient loading of VEGF small hairpin (sh)RNA to form Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites for VEGF gene silencing as well as magnetic resonance (MR) imaging. The size, morphology, particle stability, magnetic properties, and gene-binding capacity and protection were determined. Low cytotoxicity and hemolyticity against human red blood cells showed the excellent biocompatibility of the multifunctional nanocomposites, and also no significant coagulation was observed. The nanocomposites maintain their superparamagnetic property at room temperature and no appreciable change in magnetism, even after PEI modification. The qualitative and quantitative analysis of cellular internalization into MCF-7 human breast cancer cells by Prussian blue staining and inductively coupled plasma atomic emission spectroscopy analysis, respectively, demonstrated that the Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could be easily internalized by MCF-7 cells, and they exhibited significant inhibition of VEGF gene expression. Furthermore, the MR cellular images showed that the superparamagnetic iron oxide core of our Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites could also act as a T2-weighted contrast agent for cancer MR imaging. Our data highlight multifunctional Fe3O4@SiO2/PEI/VEGF shRNA nanocomposites as a potential platform for simultaneous gene delivery and MR cell imaging, which are promising as theranostic agents for cancer treatment and diagnosis in the future.

No MeSH data available.


Related in: MedlinePlus